Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that Cinqaero (reslizumab), which is under review for use as an add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment, got a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
We note that Cinqaero gained FDA approval in late Mar 2016 where it was launched under the trade name Cinqair. With the CHMP issuing a positive opinion, we believe the candidate will gain EU approval, potentially in the second half of the year.
Teva has several programs ranging from phase I to registration stage in its pipeline with many of these focused on the central nervous system (CNS) and respiratory fields. As far as other therapeutic areas like women’s health and oncology are concerned, Teva is focusing on market-ready products or late-stage candidates to maximize sustainable profitability.
Meanwhile, Teva is looking to strengthen its generics business and is set to acquire Allergan plc’s generics business for $40.5 billion. Once this deal closes, potentially by the end of this month, Teva will expand its presence as well as portfolio significantly.
Teva is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the medical sector include Pfizer, Inc. (PFE - Free Report) and Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) , both Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that Cinqaero (reslizumab), which is under review for use as an add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment, got a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
We note that Cinqaero gained FDA approval in late Mar 2016 where it was launched under the trade name Cinqair. With the CHMP issuing a positive opinion, we believe the candidate will gain EU approval, potentially in the second half of the year.
Teva has several programs ranging from phase I to registration stage in its pipeline with many of these focused on the central nervous system (CNS) and respiratory fields. As far as other therapeutic areas like women’s health and oncology are concerned, Teva is focusing on market-ready products or late-stage candidates to maximize sustainable profitability.
Meanwhile, Teva is looking to strengthen its generics business and is set to acquire Allergan plc’s generics business for $40.5 billion. Once this deal closes, potentially by the end of this month, Teva will expand its presence as well as portfolio significantly.
Teva is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the medical sector include Pfizer, Inc. (PFE - Free Report) and Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) , both Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PFE - FREE
Get the latest research report on TEVA - FREE
Get the latest research report on AMPH - FREE